Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US8324225 | NOVARTIS | Pyrrolopyrimidine compounds and their uses |
Jun, 2028
(4 years from now) | |
US8685980 | NOVARTIS | Pyrrolopyrimidine compounds and their uses |
May, 2030
(6 years from now) | |
US8415355 | NOVARTIS | Pyrrolopyrimidine compounds and their uses |
Mar, 2031
(6 years from now) | |
US9193732 | NOVARTIS | Salt(s) of 7-cyclopentyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-7H-pyrrolo[2,3-D]pyrimidine-6-carboxylic acid dimethylamide and processes of making thereof |
Nov, 2031
(7 years from now) | |
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9416136 | NOVARTIS | Pyrrolopyrimidine compounds and their uses |
Aug, 2029
(5 years from now) | |
US8962630 | NOVARTIS | Pyrrolopyrimidine compounds and their uses |
Dec, 2029
(5 years from now) | |
US9868739 | NOVARTIS | Salt(s) of 7-cyclopentyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-7H-pyrrolo[2,3-d]pyrimidine-6-carboxylic acid dimethylamide and processes of making thereof |
Nov, 2031
(7 years from now) | |
US10799506 | NOVARTIS | Ribociclib tablet |
Apr, 2036
(12 years from now) |
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
New Patient Population (NPP) | Dec 10, 2024 |
Market Authorisation Date: 04 May, 2017
Treatment: Treatment of pre/perimenopausal women with hormone receptor (hr)-positive, human epidermal growth factor receptor 2 (her2)-negative advanced or metastatic breast cancer; As initial endocrine-based the...
Dosage: TABLET;ORAL